Quick Take
AlloVir (ALVR) intends to raise $251 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is a mid stage firm developing drug treatments for virus conditions.
ALVR is preparing to enter Phase 3 trials and has an enviable position as a virus-focused biopharma with a promising pipeline in an area that is receiving strong interest by investors, researchers and government entities.
Although the IPO isn’t cheap, for life science investors with a patient hold time frame, the IPO is worth